All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

A 64-Year-Old Woman with Endometrial Cancer : Episode 6

Recurrent Metastatic EC: Common Immune-Related Adverse Events And Patient Discussions

Sep 26, 2022
Bhavana Pothuri, MD

Bhavana Pothuri, MD provides a perspective on the management of immune-related adverse events that can be seen in patients treated for recurrent metastatic endometrial cancer, as well as a focused discussion on the conversations she has with her patients.

EP: 1.Case Overview: A 64-Year-Old Woman With dMMR Metastatic Endometrial Cancer

EP: 2.Endometrial Cancer: Patient Presentation and Initial Workup

EP: 3.Systemic Therapy Options for Patients With Metastatic Endometrial Cancer

EP: 4.Dostarlimab Therapy in Recurrent Metastatic Endometrial Cancer: The GARNET Trial

EP: 5.Considerations for Second-Line Treatment Selection for Patients With Metastatic EC

Now Viewing

EP: 6.Recurrent Metastatic EC: Common Immune-Related Adverse Events And Patient Discussions

EP: 7.Metastatic Endometrial Cancer: Future Directions in Care

Transcript:

Bhavana Pothuri, MD: That’s a really important question about the differences in adverse events [AEs] that are related to immunotherapy vs chemotherapy. I talked a little about the timing of those events. One thing that’s important with immunotherapy is that unlike chemotherapy, adverse events during chemotherapy usually end with the treatment. Though patients may need several months to recover and regain their strength, the actual adverse event usually is during the treatment time.

Immunotherapy varies because even after stopping immunotherapy, you can develop an immune-related adverse event. That can even be 3 to 6 months after you stop the treatment. Having this threshold of suspicion for these adverse events, even after you stop, is important. The other thing that’s really important about these immune-related adverse events is that some of these can be fatal. Although they occur in a small percentage of patients—the serious adverse events were about 5%—if they’re not identified early and treated or the dose is held, these can be fatal. You have to be very vigilant when treating patients on immunotherapy.

When you’re dealing with colitis, you need to pay attention the patient’s baseline and then know how many stools above the baseline they’re getting. If they develop a grade 3, you have to make sure they get on high-dose steroids and that they’re improving. If you’re not hospitalizing those patients, there needs to be very close follow-up as an outpatient. If they’re not improving in 24 to 48 hours, they should be hospitalized. If they’re not improving with the high-dose steroids at 1 to 1.5 mg/kg, then you need to consider other therapies, such as infliximab. It’s also important to get GI [gastrointestinal] consultants involved in the care of these patients. That’s 1 example.

The other example is pneumonitis. If patients have a severe pneumonitis, it’s important to identify it, stop the treatment, and start high-dose steroids. The other thing about the steroids is that you need to continue steroids even if the symptoms get better. They should not be weaned off quickly. They should be weaned off over a long period of time. I don’t wean off steroids in less than 6 to 12 weeks. Keep that in mind. They shouldn’t be weaned until the adverse event is down to a grade 1.

If you look purely at the data, they’re very similar. But practically, when you utilize these drugs, I find that patients tolerate dostarlimab well. They have less reflux than some of the patients on pembrolizumab. That said, both are great drugs, and I’ve utilized both. It’s a nuanced finding because I’ve taken care of a lot of patients. But when you look at the actual data, there’s no difference.

The key to management is extensive counseling, breaking down the symptoms related to the adverse events so patients know what to look for, and training your entire team because they’re the ones who are going to be taking the phone calls when these patients are calling. You don’t want someone saying, “It’s just diarrhea. Take Imodium [loperamide].” If it’s diarrhea, then I want to know what grade it is. If it’s a high grade, then they need to come in and be seen. They need to be started on steroids. Having a thorough counseling before they start and engaging the patients to be their own advocates—writing down their adverse effects, reporting AEs early—is the key.

Transcript edited for clarity.

Related Videos
Expert on endometrial cancer
Expert on endometrial cancer
Expert on endometrial cancer
Expert on endometrial cancer
Expert on endoemtrial cancer
Expert on endometrial cancer
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Natalie Callander, MD, an expert on multiple myeloma
Related Content

Encouraging Results Support Lenvatinib/Pembrolizumab Use in Endometrial Cancer

May 1st 2023

The Evolution of Endometrial Cancer Treatment

August 15th 2022

HECTOR Deep Learning Model Predicts distant Recurrence Risk in Patients With Endometrial Cancer

April 18th 2023

Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer

April 7th 2023

Holloway Discusses Later-Line Treatment in Recurrent or Metastatic Endometrial Cancer

April 7th 2023

Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer

March 28th 2023

Encouraging Results Support Lenvatinib/Pembrolizumab Use in Endometrial Cancer

May 1st 2023

The Evolution of Endometrial Cancer Treatment

August 15th 2022

HECTOR Deep Learning Model Predicts distant Recurrence Risk in Patients With Endometrial Cancer

April 18th 2023

Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer

April 7th 2023

Holloway Discusses Later-Line Treatment in Recurrent or Metastatic Endometrial Cancer

April 7th 2023

Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer

March 28th 2023

Encouraging Results Support Lenvatinib/Pembrolizumab Use in Endometrial Cancer

May 1st 2023

The Evolution of Endometrial Cancer Treatment

August 15th 2022

HECTOR Deep Learning Model Predicts distant Recurrence Risk in Patients With Endometrial Cancer

April 18th 2023

Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer

April 7th 2023

Holloway Discusses Later-Line Treatment in Recurrent or Metastatic Endometrial Cancer

April 7th 2023

Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer

March 28th 2023
Related Content

Encouraging Results Support Lenvatinib/Pembrolizumab Use in Endometrial Cancer

Encouraging Results Support Lenvatinib/Pembrolizumab Use in Endometrial Cancer

May 1st 2023
Article

The combination of lenvatinib and pembrolizumab continued to show benefits in efficacy vs chemotherapy among patients with endometrial cancer treated in Study 309/KEYNOTE-775.

Read More


The Evolution of Endometrial Cancer Treatment

The Evolution of Endometrial Cancer Treatment

August 15th 2022
Podcast

In season 3, episode 7 of Targeted Talks, John Nakayama, MD, discusses updates in the endometrial cancer treatment landscape.

Listen


HECTOR Deep Learning Model Predicts distant Recurrence Risk in Patients With Endometrial Cancer

HECTOR Deep Learning Model Predicts distant Recurrence Risk in Patients With Endometrial Cancer

April 18th 2023
Article

An artificial intelligence model has been shown to predict the risk of low and high distant recurrence in patients with endometrial cancer.

Read More


Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer

Dostarlimab Plus Chemo Designated SOC for Primary Advanced/Recurrent Endometrial Cancer

April 7th 2023
Article

The addition of dostarlimab to standard combination chemotherapy in the phase 3 RUBY study showed a significant survival improvement in patients with primary advanced or recurrent endometrial cancer.

Read More


Holloway Discusses Later-Line Treatment  in Recurrent or Metastatic Endometrial Cancer

Holloway Discusses Later-Line Treatment in Recurrent or Metastatic Endometrial Cancer

April 7th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™, Robert W. Holloway, MD, discussed with participants later-line systemic therapy options for patients with recurrent/metastatic endometrial cancer.

Read More


Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer

Addition of Dostarlimab to Chemotherapy Represents New Standard of Care in Endometrial Cancer

March 28th 2023
Article

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.